$7.02 +0.04 (0.57%)

Actuate Therapeutics, Inc. Common stock (ACTU)

Actuate Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing targeted therapies for the treatment of cancer and inflammatory diseases. The company is known for its research and development efforts aimed at addressing unmet medical needs through innovative drug candidates.

🚫 Actuate Therapeutics, Inc. Common stock does not pay dividends

Company News

Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option
Benzinga • Globe Newswire • September 11, 2025

Actuate Therapeutics successfully closed a $17.25 million public offering of 2,464,286 common stock shares at $7.00 per share, including the full exercise of an over-allotment option. The company plans to use the net proceeds of approximately $15.62 million for working capital and general corporate purposes.

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
GlobeNewswire Inc. • N/A • May 31, 2025

Actuate Therapeutics' Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel for first-line treatment of metastatic pancreatic ductal adenocarcinoma met its primary endpoint, demonstrating a clinically meaningful increase in median overall survival.